Here's Why Inozyme Pharma (INZY) is Poised for a Turnaround After Losing -29.98% in 4 Weeks

Group 1 - Inozyme Pharma, Inc. (INZY) has experienced a significant downtrend, with a 30% decline in stock price over the past four weeks, indicating excessive selling pressure [1] - The stock is currently in oversold territory, as indicated by its Relative Strength Index (RSI) reading of 28.72, suggesting a potential for a price reversal [3] - Analysts have raised earnings estimates for INZY by 4.2% over the last 30 days, indicating a strong consensus among sell-side analysts that could lead to price appreciation [3] Group 2 - The Zacks Rank for INZY is 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the potential for a turnaround [3]